Sophia Genetics SA

Company Profile

Sophia Genetics SA had its IPO on 2021-07-23 under the ticker symbol SOPH.

The company operates in the Healthcare sector and Health Information Services industry. Sophia Genetics SA has a staff strength of 466 employees.

Stock update

Shares of Sophia Genetics SA opened at $2.46 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.46 - $2.55, and closed at $2.52.

This is a +2.86% increase from the previous day's closing price.

A total volume of 8,121 shares were traded at the close of the day’s session.

In the last one week, shares of Sophia Genetics SA have increased by +3.7%.

Sophia Genetics SA's Key Ratios

Sophia Genetics SA has a market cap of $158.03 million, indicating a price to book ratio of 0.7017 and a price to sales ratio of 3.3164.

In the last 12-months Sophia Genetics SA’s revenue was $54.05 million with a gross profit of $31.25 million and an EBITDA of $-75591000. The EBITDA ratio measures Sophia Genetics SA's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Sophia Genetics SA’s operating margin was -144.28% while its return on assets stood at -19.48% with a return of equity of -39.21%.

In Q2, Sophia Genetics SA’s quarterly earnings growth was a positive 0% while revenue growth was a positive 29%.

Sophia Genetics SA’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.19 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Sophia Genetics SA’s profitability.

Sophia Genetics SA stock is trading at a EV to sales ratio of 0.1242 and a EV to EBITDA ratio of 0.3174. Its price to sales ratio in the trailing 12-months stood at 3.3164.

Sophia Genetics SA stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$223.20 million

Total Liabilities

$31.55 million

Operating Cash Flow

$0

Capital Expenditure

$3.15 million

Dividend Payout Ratio

0%

Sophia Genetics SA ended 2024 with $223.20 million in total assets and $0 in total liabilities. Its intangible assets were valued at $223.20 million while shareholder equity stood at $171.70 million.

Sophia Genetics SA ended 2024 with $0 in deferred long-term liabilities, $31.55 million in other current liabilities, 4048000.00 in common stock, $-339899000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $148.55 million and cash and short-term investments were $148.55 million. The company’s total short-term debt was $3,466,000 while long-term debt stood at $0.

Sophia Genetics SA’s total current assets stands at $168.57 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $9.85 million compared to accounts payable of $6.55 million and inventory worth $5.46 million.

In 2024, Sophia Genetics SA's operating cash flow was $0 while its capital expenditure stood at $3.15 million.

Comparatively, Sophia Genetics SA paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$2.52

52-Week High

$5.77

52-Week Low

$1.685

Analyst Target Price

$7

Sophia Genetics SA stock is currently trading at $2.52 per share. It touched a 52-week high of $5.77 and a 52-week low of $5.77. Analysts tracking the stock have a 12-month average target price of $7.

Its 50-day moving average was $3.36 and 200-day moving average was $3.54 The short ratio stood at 0.5 indicating a short percent outstanding of 0%.

Around 484.8% of the company’s stock are held by insiders while 5247.4% are held by institutions.